Circulating 1,5-anhydroglucitol as a biomarker of ß-cell mass independent of a diabetes phenotype in human subjects

Cecilia Jiménez-Sánchez, Teresa Mezza, Flore Sinturel, Lingzi Li, Gianfranco Di Giuseppe, Giuseppe Quero, François R Jornayvaz, Idris Guessous, Charna Dibner, Patrick Schrauwen, Sergio Alfieri, Andrea Giaccari*, Pierre Maechler*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

182 Downloads (Pure)

Abstract

CONTEXT: During an asymptomatic pre-diabetic state, the functional ß-cell mass decreases up to a critical threshold triggering diabetes and related symptoms. To date, there are no reliable readouts able to capture in vivo a potential drop of the ß-cell mass.

OBJECTIVE: Beside its use as a short-term marker of glycemic control, the deoxyhexose 1,5-anhydroglucitol was identified in rodents as a circulating biomarker of the functional ß-cell mass already in the asymptomatic prediabetic stage. The present study investigated the putative corresponding relevance of circulating 1,5-anhydroglucitol in different human cohorts.

METHODS: We analyzed clinical and blood parameters in patients with established type 2 diabetes and subjects considered at high risk of developing diabetes, as well as patients with no history of diabetes scheduled for pancreaticoduodenectomy.

RESULTS: Circulating 1,5-anhydroglucitol was reduced in type 2 diabetic patients, negatively correlating with fasting plasma glucose (p<0.0001) and HbA1c (p<0.0001). In healthy subjects, 1,5-AG levels positively correlated with body mass index (p=0.004) and HOMA%S (p<0.03) and was particularly high in nondiabetic obese individuals, potential accounting for compensatory ß-cell expansion. Patients with no history of diabetes undergoing pancreaticoduodenectomy exhibited a 50% reduction of circulating 1,5-anhydroglucitol levels following surgery leading to an acute loss of their ß-cell mass (p=0.002), regardless their glucose tolerance status.

CONCLUSION: In summary, plasma concentration of 1,5-anhydroglucitol follows the ß-cell mass and its non-invasive monitoring may alert about the loss of ß-cells in subjects at risk for diabetes, an event that cannot be captured by other clinical parameters of glycemic control.

Original languageEnglish
Pages (from-to)2833-2843
Number of pages11
JournalJournal of Clinical Endocrinology & Metabolism
Volume107
Issue number10
Early online date22 Jul 2022
DOIs
Publication statusPublished - 28 Sept 2022

Keywords

  • 1
  • 1,5-ANHYDRO-D-GLUCITOL
  • 5-anhydroglucitol
  • CLINICAL MARKER
  • IMPAIRED GLUCOSE-TOLERANCE
  • INSULIN SENSITIVITY
  • LEVEL
  • PATHOGENESIS
  • PLASMA 1,5-ANHYDROGLUCITOL
  • PREVENTION
  • RESISTANCE
  • SERUM 1,5-ANHYDROGLUCITOL
  • biomarker
  • diabetes
  • glycemic control
  • prediabetes
  • ss-cell mass

Fingerprint

Dive into the research topics of 'Circulating 1,5-anhydroglucitol as a biomarker of ß-cell mass independent of a diabetes phenotype in human subjects'. Together they form a unique fingerprint.

Cite this